Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 in Advanced NSCLC With EGFR Mutations
NCT05559645Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of sunvozertinib in non-small cell lung cancer (NSCLC) (8 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-Free Survival at 1 year. Started Nov 2021; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05559645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559645.